No Data
No Data
No Data
No Data
No Data
89bio Coverage Assumed by B of A Securities at Buy
89bio Coverage Assumed by B of A Securities at Buy
Dow JonesApr 22 06:24 ET
Express News | B of A Securities Assumes 89bio at Buy, Announces Price Target of $30
Moomoo 24/7Apr 22 06:14 ET
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 19 17:10 ET
89bio Enhances Board With Biopharma Veteran Martin Babler
TipRanksApr 17 16:22 ET
Express News | 89Bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
Moomoo 24/7Apr 17 16:05 ET
89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
PDF Version SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovati
89bioApr 17 00:00 ET
No Data
No Data